Get to know our clinical trials

Trial of Radspherin® in patients with recurrent platinum-sensitive primary ovarian epithelial, fallopian tube or peritoneal epithelial carcinoma with peritoneal carcinomatosis after complete surgical resection.

THIS STUDY IS BEING DONE TO FIND OUT IF THE STUDY DRUG (RADSPHERIN®) CAN HELP PEOPLE WITH OVARIAN CANCER.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE 1 STUDY TO EVALUATE THE DOSE, SAFETY AND TOLERABILITY OF AN INTRAPERITONEAL TREATMENT WITH EMITTING RADIONUCLIDES ? (RADSPHERIN®) IN PATIENTS WITH RECURRENT PLATINUM-SENSITIVE PRIMARY OVARIAN EPITHELIAL, FALLOPIAN TUBE OR PERITONEAL EPITHELIAL CARCINOMA WITH PERITONEAL CARCINOMATOSIS AFTER COMPLETE SURGICAL RESECTION.
  • Code EudraCT: 2018-002802-29
  • Protocol number: RAD-18-001
  • Promoter: Oncoinvent AS
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.